Deutsche Bank AG Acquires Shares of 320,037 Natera, Inc. $NTRA

Deutsche Bank AG bought a new stake in Natera, Inc. (NASDAQ:NTRA) during the 2nd quarter, HoldingsChannel reports. The fund bought 320,037 shares of the medical research company’s stock, valued at approximately $86,874,000.

Several other institutional investors have also recently made changes to their positions in NTRA. Perigon Wealth Management LLC bought a new position in Natera during the 2nd quarter valued at about $622,000. Trust Co. of Vermont bought a new stake in Natera in the second quarter worth about $26,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Natera in the second quarter worth about $50,424,000. OneDigital Investment Advisors LLC purchased a new position in shares of Natera during the second quarter valued at approximately $460,000. Finally, Abbot Financial Management Inc. purchased a new position in shares of Natera during the second quarter valued at approximately $1,537,000. Institutional investors own 99.90% of the company’s stock.

Insider Activity

In related news, Director Roelof Botha sold 78,000 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the completion of the transaction, the director directly owned 1,076,198 shares of the company’s stock, valued at $237,097,181.38. This trade represents a 6.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 41,124 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the sale, the chief executive officer directly owned 108,743 shares in the company, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 181,045 shares of company stock valued at $41,330,968. 5.05% of the stock is owned by company insiders.

Natera Trading Down 0.1%

Shares of NASDAQ:NTRA opened at $324.84 on Friday. The company has a market capitalization of $46.82 billion, a PE ratio of -238.85 and a beta of 1.51. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $333.56. The business’s fifty day simple moving average is $271.84 and its 200-day simple moving average is $228.67.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. Natera’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.74) earnings per share. Research analysts predict that Natera, Inc. will post -1.02 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on NTRA shares. Stephens increased their price target on Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Guggenheim boosted their price objective on Natera from $290.00 to $360.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Robert W. Baird set a $348.00 price objective on Natera in a research report on Friday, August 7th. Sanford C. Bernstein started coverage on Natera in a research note on Friday, June 26th. They issued an “outperform” rating and a $310.00 target price on the stock. Finally, Wells Fargo & Company lifted their target price on Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and an average price target of $319.38.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.